SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRtw Biotech Regulatory News (RTW)

Share Price Information for Rtw Biotech (RTW)

Share Price is delayed by 15 minutes
Get Live Data
2.21    0.00 (0.00%)
Bid:
2.19
Ask:
2.21
Spread: 0.02 (0.913%)
Market Cap: $714.60m
RTW Live PriceLast checked at - London Stock Exchange

Intraday Rtw Biotech Share Chart

Monthly Valuation Update and Factsheet

14 Feb 2025 07:00

RNS Number : 0864X
RTW Biotech Opportunities Ltd
14 February 2025
 

LEI: 549300Q7EXQQH6KF7Z84

14 February 2025

RTW Biotech Opportunities Ltd

Monthly Valuation Update and Factsheet

+4.3% NAV movement for the month

RTW Biotech Opportunities Ltd (the "Company") announces that the unaudited net asset value attributable to the ordinary shares of the Company at the close of business on 31 January 2025 (the "NAV") was US$632.8 million, or US$1.89 per ordinary share, +4.3% from the previous month.

The monthly factsheet is available on the Company's website:

 

https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/factsheets-letters/

 

 

For Further Information

RTW Investments, LP

+44 20 7959 6361

Woody Stileman, Managing Director, Business Development

Krisha McCune, Director, Investor Relations

biotechopportunities@rtwfunds.com

 

Cadarn Capital (PR & Communications / Distribution & IR Partner)

Lucy Clark (PR)

David Harris (Distribution)

 

 

Deutsche Numis (Joint Corporate Broker)

 

+44 79 8418 4461

Lucy@cadarncapital.com

+44 73 6888 3211

david@cadarncapital.com

 

+44 20 7260 1000

Freddie Barnfield

 

Nathan Brown

 

Euan Brown

 

 

BofA Securities (Joint Corporate Broker)

+44 20 7628 1000

Edward Peel

 

Alex Penney

 

 

Altum (Guernsey) Limited (previously named Elysium Fund Management Limited)

 

+44 14 8170 3100

 

Joanna Duquemin Nicolle, Director

 

 

Sadie Morrison, Director

 

 

Morgan Stanley Fund Services USA LLC

+1 914 225 8885

 

About Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd for more information.

***********

The information in this announcement may include forward-looking statements, which are based on the current expectations and projections about future events, and in certain cases can be identified by the use of terms such as "may", "will", "should", "expect", "anticipate", "project", "estimate", "intend", "continue", "target", "believe" (or the negatives thereon) or other variations thereon or comparable terminology. These forward-looking statements, as well as those included in any related materials, are subject to risks, uncertainties and assumptions about the Company and/or its underlying investments, including, among other things, the development of the applicable entity's business, trends in its operating industry, expected use of financing proceeds and future capital expenditures and acquisitions. In light of these risks, uncertainties and assumptions, the events in the forward-looking statements may not occur.

The information contained in this announcement is given at the date of its publication (unless otherwise marked). No reliance may be placed for any purpose whatsoever on the information or opinions contained in this announcement or on its completeness, accuracy or fairness.

***********

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DOCDXLFFELLEBBK
Date   Source Headline
8th Feb 20217:00 amRNSPortfolio Company Update: Immunocore IPO
5th Feb 20217:00 amRNSPortfolio Company Update: Landos IPO
1st Feb 20217:00 amRNSTotal Voting Rights
1st Feb 20217:00 amRNSChange of Administrator and Company Secretary
25th Jan 202110:04 amRNSDirector/PDMR Shareholding
22nd Jan 20217:00 amRNSQuarterly Update
19th Jan 20216:11 pmRNSIssue of Equity
15th Jan 20213:39 pmRNSAnnouncement of Share Issuance
15th Jan 20217:00 amRNSNet Asset Value
11th Jan 202112:22 pmRNSAdditional Investment in Portfolio Company
6th Jan 20213:30 pmRNSNew Investment in Biomea Fusion
29th Dec 202010:16 amRNSDirector/PDMR Shareholding
24th Dec 20208:35 amRNSDirector/PDMR Shareholding
23rd Dec 20209:07 amRNSDirector/PDMR Shareholding
14th Dec 20207:00 amRNSNet Asset Value(s)
10th Dec 20207:00 amRNSTransformational Update from Largest Holding
8th Dec 20208:03 amRNSNew Investment in Nuance Pharma
1st Dec 20207:00 amRNSTotal Voting Rights
16th Nov 20205:59 pmRNSIssue of Equity
13th Nov 20206:22 pmRNSAnnouncement of Share Issuance
13th Nov 20207:00 amRNSNet Asset Value(s)
10th Nov 20209:26 amRNSHolding(s) in Company
9th Nov 20202:00 pmRNSNew Investment in Prometheus Biosciences
2nd Nov 20207:00 amRNSTotal Voting Rights
28th Oct 20201:25 pmRNSHolding(s) in Company
19th Oct 20207:01 amRNSTarsus Pharmaceuticals Prices $88 Million IPO
19th Oct 20207:00 amRNSQuarterly Update
16th Oct 20205:19 pmRNSIssue of Equity
14th Oct 20202:31 pmRNSAnnouncement of Share Issuance
14th Oct 20207:00 amRNSNet Asset Value(s)
5th Oct 20207:00 amRNSC4 Therapeutics Prices $182 Million IPO
2nd Oct 20207:00 amRNSPulmonx Prices $190 Million IPO
28th Sep 20204:13 pmRNSHolding(s) in Company
24th Sep 20207:00 amRNSInterim Report for the period ended 30 June 2020
21st Sep 20207:00 amRNSAthira Pharma Prices $204.0 Million IPO
15th Sep 20207:00 amRNSNet Asset Value(s)
14th Sep 20201:00 pmRNSSeries B Financing Round in NiKang Therapeutics
2nd Sep 20207:00 amRNSNotice of Interim Report
1st Sep 20207:00 amRNSTotal Voting Rights
17th Aug 20205:16 pmRNSIssue of Equity
14th Aug 20202:01 pmRNSAnnouncement of Share Issuance
14th Aug 20207:00 amRNSNet Asset Value(s)
12th Aug 20207:00 amRNSPortfolio Company Update
3rd Aug 20207:00 amRNSTotal Voting Rights
28th Jul 20206:25 pmRNSHolding(s) in Company
27th Jul 20207:00 amRNSiTeos Therapeutics Prices $201 Million IPO
23rd Jul 202012:00 pmRNSNew Investment in Milestone Pharmaceuticals
22nd Jul 20201:00 pmRNSSeries D Financing in Encoded Therapeutics
21st Jul 20207:00 amRNSQuarterly Update
17th Jul 202011:44 amRNSIssue of Equity - Replacement Announcement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.